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Summary
Objective: To analyse the relationship between the levels of urinary biochemical markers of type II collagen degradation and the clinical and
radiological severity and progression of knee osteoarthritis (OA).
Method: Seventy-ﬁve patients with primary knee OA were included in this 3-year follow-up study. Mean joint space width (JSW) of the medial
compartment of the femorotibial joint was measured with a computer assisted method on standardized radiographs taken at baseline and after
a 3-year follow-up. Pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities (WOMAC) were
assessed at the same time points. Type II collagen peptides Coll 2-1 and Coll 2-1 NO2, as well as pyridinoline (Pyr) and deoxypyridinoline
(D-Pyr) were measured in urines at baseline, after 1 year and 3 years, with speciﬁc immunoassays.
Results: At baseline, signiﬁcant correlations were found between the urinary Coll 2-1 and Coll 2-1 NO2 levels and the global WOMAC score
(Coll 2-1: rZ 0.28, PZ 0.01; Coll 2-1 NO2: rZ 0.27, PZ 0.02) and its subscales for pain (Coll 2-1: rZ 0.27, PZ 0.01; Coll 2-1 NO2: rZ 0.30,
PZ 0.01) and function (Coll 2-1: rZ 0.29, PZ 0.01; Coll 2-1 NO2: rZ 0.27, PZ 0.02). Pyr and D-Pyr levels were not signiﬁcantly correlated
with the WOMAC scores. One-year change in Coll 2-1 and Coll 2-1 NO2 urinary levels were negatively correlated with a 3-year change in JSW
(Coll 2-1: rZ0.31, PZ 0.03; Coll 2-1 NO2: rZ0.31, PZ 0.03), indicating that an increase of Coll 2-1 or Coll 2-1 NO2 over 1 year is
predictive of subsequent joint space narrowing. Neither Pyr nor D-Pyr was correlated with radiological OA progression.
Conclusions: At baseline, Coll 2-1 and Coll 2-1 NO2 urinary levels were indicative of the clinical activity of knee OA and the increase of these
peptides over 1 year was predictive of the radiological progression of knee OA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Osteoarthritis (OA) is one of the major causes of pain and
disability in adult people and is among the most frequent
form of musculoskeletal diseases. One challenge for the
future is to develop new tools for the evaluation of the
efﬁcacy of therapeutic interventions on progression of
structural joint damage in OA. Usually, OA progression is
monitored by the measurement of changes in joint space
width (JSW) on plain X-ray with a graduated magnifying
lens or with a computer after digitisation of the radiograph.
This must be considered a rather indirect measure of
cartilage integrity, as articular cartilage itself is invisible
on the radiographs and thus has to be assessed indirectly
from the spacing between the subchondral bone ends of
the joint. Furthermore, JSW measurement does not allow
detection of early structural damage and remains cumber-
some to use in daily practice. Alternatively, biochemical
markers of bone, synovium or cartilage turnover have been
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Received 19 April 2005; revision accepted 30 June 2005.105proposed as potential tools for the diagnosis, prognosis and
treatment monitoring of OA1e8. In this work, we have
investigated the value of pyridinoline (Pyr), deoxypyridino-
line (D-Pyr) and peptides of type II collagen molecule
[108HRGYPGLDG116 (Coll 2-1), 108HRGY(NO2)PGLDG
116
(Coll 2-1 NO2)] to predict knee OA progression. Pyr and
D-Pyr are crosslinks between mature collagen molecules,
being primarily found in bone and cartilage but not in
skin9,10. Total excretion of Pyr and especially D-Pyr can be
used as an index of bone resorption even though neither
one of thesemarkers is bone speciﬁc11. In kneeOA patients,
Pyr and D-Pyr levels have been reported to be elevated
compared to controls12.
Type II collagen has been frequently studied as a potential
biochemical marker for cartilage remodelling. The reasons
were that type II collagen is the major structural molecule in
cartilage and that this collagen is very speciﬁc of cartilage.
Type II collagen is composed of a triple helix of three
identical a chains, which associate to form a ﬁbril that is
stabilized by intermolecular crosslinks. The ﬁbrils provide
the tensile strength and maintain the integrity of articular
cartilage by forming a network that resists the forces
generated by mechanical strains and the swelling pressure
resulting from the hydrated aggrecans. Damage to this
ﬁbrillar meshwork is a critical event in the pathogenesis of9
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(RA), due in part to the very slow rate of collagen turnover in
adult cartilage. Some immunohistochemical studies have
clearly evidenced type II collagen damage in OA cartilage
by using antibodies directed against collagenase-induced
neopitopes2,13,14. This ﬁnding supports the concept that
peptides released from type II collagen during cartilage
degradation could be markers of arthritis onset and/or
progression. Two main strategies have been developed for
evaluating type II collagen processing. One strategy con-
sists of measuring type II collagen propeptide, as amarker of
type II synthesis. In human OA cartilage, the serum levels of
the C-propeptide (CPII) was elevated compared with normal
adults, but no correlation with the cartilage lesion severity
determined by the Mankin score was found15. Further, the
increase in CPII in OA cartilage was not reﬂected in serum
where a signiﬁcant reduction was observed compared
with control15. The second strategy was to measure type II
collagen peptides released during collagen network degra-
dation. The C-telopeptide fragment (CTX-II) was found
increased in urine of OA patients compared to healthy
controls4,6,16e18. Furthermore, CTX-II concentration was
negatively correlated with the minimum JSW in gonarth-
rosis4 and in coxarthrosis19. Recently, Garnero et al.6
reported that a low level of serum N-propeptide of type IIA
procollagen coupled to a high level of CTX-II, was predictive
of progression of joint damage in knee OA.
Herein, we used a new approach for quantifying type II
collagen network degradation in OA20. This approach is
based on the detection in urine of a peptide released from
the triple helix of type II collagen in its native or nitrated
form. Peptide nitration results from the reaction of aromatic
amino acids with peroxynitrite (ONOO), a strong oxidant
formed by the reaction of nitric oxide (cNO) and superoxide
anion(O2
c ). In OA, cNO and O2
c are produced by a large
number of cells including macrophages and chondro-
cytes21,22. Tyrosine, tryptophan and phenylalanine are
particularly sensitive to nitration23. Type II collagen a chain
contains two tyrosines, one located in the triple helix and
the other in the telopeptide at the C-terminal end. We have
developed two new speciﬁc immunoassays: one for the
108HRGYPGLDG116 sequence (Coll 2-1) and the other for
the nitrated form of this peptide 108HRGY(NO2)PGLDG
116
(Coll 2-1 NO2)
20. Coll 2-1 is located in the triple helix of
type II collagen molecule. In healthy subjects, the concen-
trations of Coll 2-1 in serum remained stable over life. In
contrast, Coll 2-1 NO2 concentration is more elevated in
young subjects (26e30 years old). These two markers were
not affected by the circadian rythm24. We have also
demonstrated that Coll 2-1 and Coll 2-1 NO2 concentrations
were elevated in serum of patients with primary knee OA
and early RA compared to healthy subjects20.
In this study, we investigated the value of single (at
baseline) or repeated (at 12-month interval) measurements
of Coll 2-1, Coll 2-1 NO2, Pyr and D-Pyr in urine to assess
the severity of and predict long-term (36-month) progres-
sion of knee OA.
Materials and methods
PATIENTS WITH KNEE OA
We investigated 75 patients (60 women, 15 men), mean
age: 65.8 years, with primary knee OA diagnosed according
to the clinical and radiological criteria of the American
College of Rheumatology25. At inclusion, disease severity
was graded on the basis of the Kellgren and Lawrenceradiographic scoring system. These patients were part of
the placebo arm of a large 3 years, randomised, double-
blind study comparing the efﬁcacy of glucosamine sulphate
with placebo26. Major exclusion criteria were: history or
active presence of other rheumatic diseases that could be
responsible for secondary OA; severe articular inﬂamma-
tion as conﬁrmed by physical examination (excluded also
by erythrocyte sedimentation rate !40 mm/h and serum
rheumatoid factor titre !1:40); traumatic knee lesions;
overweight deﬁned as a body mass index (BMI) O30;
substantial abnormalities in haematological, hepatic, renal,
or metabolic functions; and intra-articular or systemic ad-
ministration of corticosteroids in the 3 months preceding
enrolment. Urine samples were collected at the inclusion,
after 1 year and 3 years and stored at 20(C until analysis.
The study was approved by the ethic committee of the
University of Lie`ge and all patients gave their oral and
written informed consent to participate.
RADIOGRAPHIC ASSESSMENT
Weightbearing, anteroposterior, separate radiographs of
each knee were taken at baseline and after 3 years by
a standardized technique27. In brief, patients stood with
their knees fully extended and the posterior aspect of the
knee in contact with the vertical cassette. The lower limbs
were rotated until the patella was centralised over the lower
end of the femur. Feet were positioned a small distant apart:
foot maps were used for repositioning the patient. The X-ray
beam was centred on the joint space and parallel to the
tibial plateau. Fluoroscopy was used to correct lower limb
positioning and X-ray beam alignment. The focus to ﬁlm
distance was 110 cm.
We digitised the radiographs and did the image analysis
automatically by a validated system28, which located the
proximal and distal joint margins excluding outlier points and
calculated the mean JSW of the medial compartment of the
tibiofemoral joint29. We calculated the mean (SD) short-term
and long-term coefﬁcient of variation (CVs) of this system
for reproducing measurements as 1.82% (1.29) and 1.62%
(1.31), respectively, for the medial compartment of the
tibiofemoral joint, which is in good agreement with the 1.84%
CV reported in the original validation of this method30.
SYMPTOMS OF OA
At baseline and after 3 years, symptoms of OA were
evaluated by the Western Ontario and McMaster Uni-
versities (WOMAC) index, a validated, disease-speciﬁc
questionnaire addressing the severity of joint pain
(ﬁve questions), stiffness (two questions), and limitation of
physical function (17 questions), and referring to the 48 h
before assessment31. The visual analogue scale version of
the index was used, with the patient assessing each
question by a 100 mm visual scale, and the total index
score being represented by the sum of the 24 item scores.
A higher WOMAC score represents worse symptom
severity, with 2400 mm being the worst possible total score.
IMMUNOASSAYS FOR CARTILAGE DEGRADATION
BIOMARKERS (COLL 2-1 AND COLL 2-1 NO2)
Urinary Coll 2-1 and Coll 2-1 NO2 concentrations were
measured by two new competitive and speciﬁc immuno-
assays20. The Coll 2-1 immunoassay only detects the
amino acid sequence in its linear form while the Coll 2-1
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afﬁnity the nitrated amino acids sequence.
Immunoassay for Coll 2-1 peptide
Brieﬂy, Coll 2-1 conjugated to bovine serum albumin
(BSA) by the covalent cross-linker bis-(sulfosuccinimidyl)-
suberate (BS3), was coated by adding 100 ml of a solution at
50 ng/ml for 48 h at 4(C. The coated immunoplates were
blocked with 400 ml/wells of saturation buffer (1.5 mM
KH2PO4, 8 mM Na2HPO4, 2 mM KCl, 138 mM NaCl, 05%
[w/v] BSA, 53 mg/ml Lactose monohydrate) pH 7.2 during
90 min at room temperature. After washing with 25 mM Tris,
50 mM NaCl, 0.1% (v/v) Tween 20 pH 7.2, 50 ml of
calibrators or unknown samples was mixed with 100 ml of
the antiserum (D3), diluted 1/40,000 in 10 mM phosphate
buffer saline (PBS), 138 mM NaCl, 0.2% (w/v) BSA, 0.1%
(v/v) Tween 20 pH 7.0, and incubated for 1 h at room
temperature (incubation buffer). After washing, 100 ml of
peroxidase-conjugated goat antibodies to rabbit IgG (Bio-
source, Belgium), diluted 1/5000 in incubation buffer, were
incubated for 1 h at room temperature. After washing,
100 ml of freshly prepared enzyme substrate (TMB)
was added into each well. After 15 min, the reaction was
stopped with 100 ml of 4 M H3PO4. The colouration was
read with a microplate reader (Labsystem, Finland) at
450 nm, corrected for absorbance at 650 nm. This assay
only recognized Coll 2-1 and not native or heat denatured
type I and II collagens20. The limit of detection was 17 nM.
The intra- and inter-assay CVs in urine were lower than
10%. The dilution curves were parallel to the standard curve
and the analytical recovery was in mean 110.9%.
Immunoassay for Coll 2-1 NO2
Coll 2-1 NO2 was conjugated to biotin according to the
method of Rosenquist et al.32. One hundred microlitres of
this biotinylated peptide was incubated at 1.25 ng/ml on
streptavidine-coated plates (Exiqon, Denmark) during 1 h at
room temperature. Fifty microlitres of calibrators or un-
known samples was mixed with 100 ml of the antiserum
D37, diluted 1/500,000 in 50 mM Tris, 138 mM NaCl, 0.2%
(w/v) BSA, 0.1% (v/v) Tween 20 pH 8.0 (incubation buffer),
and incubated for 1 h at room temperature. The detection of
the antibody bound and the revelation were realized
using the same procedure as described for Coll 2-1
enzyme-linked immunosorbant assay (ELISA). This assay
is highly speciﬁc for the nitrated form of Coll 2-120. The limit
of detection was 25 pM. The intra- and inter-assay CVs in
urine were lower than 15%. The dilution curves were
parallel to the standard curve and the analytical recovery
was in mean 119.7%.
IMMUNOASSAYS FOR PYR AND D-PYR
Urine Pyr and D-Pyr were measured using the Pyrilinks
and Pyrilinks-D competitive enzyme immunoassays (EIA)
(Metra Biosystems, Mountain View, CA, USA). The limit of
detection was 7.5 nM for Pyr and 1.1 nM for D-Pyr. For the
two methods, the within- and between-assay CVs were
below 10%.
Coll 2-1, Coll 2-1 NO2, Pyr and D-Pyr were corrected for
variations in urine concentration by expressing the results
as nM/mM creatinine. The creatinine was measured by the
method of Jaffe´33 on a MEGA autoanalyzer (Merck,
Germany).STATISTICAL METHODS
The Coll 2-1 and Coll 2-1 NO2 values were expressed as
median (minimum and maximum) and, the clinical and the
radiological markers, Pyr and D-Pyr values were expressed
as meanG standard deviation (SD). The ratio of Coll 2-1
NO2/Coll 2-1 was also calculated. Relationships between
biochemical markers and clinical or radiological severity of
knee OA were assessed by the calculation of Spearman’s
correlation coefﬁcient. To evaluate the predictive quality of
these markers, we assessed the links between baseline
or 1-year changes in markers and the 3-year changes in
symptoms or structure. The results were considered
signiﬁcant at the 5% level (P! 0.05). Statistical calcula-
tions were carried out with the SAS software (SAS Institute,
Cary, NC, USA).
Results
Baseline characteristics of the studied population are
summarized in Table I. At baseline, none of the biochemical
markers studied were signiﬁcantly correlated with demo-
graphic characteristics (age, sex and BMI: P between 0.41
and 0.95 for all markers). Coll 2-1 and Coll 2-1 NO2, but not
Pyr, D-Pyr or Coll 2-1 NO2/Coll 2-1, were positively and
signiﬁcantly correlated with the global WOMAC score
(Coll 2-1: rZ 0.28, PZ 0.01; Coll 2-1 NO2: rZ 0.27,
PZ 0.02) and its subscales for pain (Coll 2-1: rZ 0.27,
PZ 0.01; Coll 2-1 NO2: rZ 0.30, PZ 0.01) and function
(Coll 2-1: rZ 0.29, PZ 0.01; Coll 2-1 NO2: rZ 0.27,
PZ 0.02), but not with stiffness. In other words, these data
indicate that Coll 2-1 or Coll 2-1 NO2 levels are more
elevated in OA patients with more severe OA clinical
symptoms and disability. The total WOMAC worsened by
9.8% (95% CI 14.6 to 34.3%) over 3 years (Table II).
Baseline values of the biochemical markers were not
signiﬁcantly correlated with the 3-year changes of WOMAC
score (total, pain, stiffness and function) (data not shown).
Similarly, no signiﬁcant correlations were found between
Table I
Demographic and baseline characteristics of the population
(nZ 75)
Variables Mean (SD)
Women 60
Age (years) 65.85 (7.34)
BMI (kg/m2) 27.25 (2.84)
WOMAC index
Total index* (mm) 882.87 (458.61)
Pain (mm) 158.13 (97.85)
Stiffness (mm) 94.79 (55.67)
Function (mm) 629.95 (352.57)
Mean JSW (mm) 5.30 (1.32)
Biological markers
Pyr (nM/mM creatinine) 31.92 (12.04)
D-Pyr (nM/mM creatinine) 6.37 (2.34)
Coll 2-1 (nM/mM creatinine) 5.06 (1.47e33.45)
Coll 2-1 NO2 (nM/mM creatinine) 0.02 (0.00e0.38)
Coll 2-1 NO2/Coll 2-1 (%) 0.29 (0.00e4.06)
Values were expressed as means (SD) except for Coll 2-1, Coll
2-1 NO2 and the ratio of Coll 2-1 NO2/Coll 2-1 for which the values
were medians (range).
*Sum of visual analogue scale scores.
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Average total WOMAC percent change, joint space narrowing and biochemical markers change after 1 year and 3 years
Variables 1-year changes (nZ 58) 3-year changes (nZ 46)
Total WOMAC (%) 1.92 (78.80) 9.80 (102.61)
Pain (%) 8.80 (96.03) 34.30 (172.30)
Function (%) 6.36 (113.87) 17.40 (117.97)
Stiffness (%) 30.86 (244.24) 3.90 (120.84)
Mean JSW (mm) e 0.31 (1.10)
Biological markers
Pyr (nM/mM creatinine) 1.83 (10.11) 5.39 (12.30)
D-Pyr (nM/mM creatinine) 0.85 (1.57) 1.58 (3.61)
Coll 2-1 (nM/mM creatinine) 1.34 (27.78 to 5.22) 0.48 (31.22 to 17.71)
Coll 2-1 NO2 (nM/mM creatinine) 0.01 (0.24 to 0.26) 0.01 (0.35 to 0.33)
Coll 2-1 NO2/Coll 2-1 (%) 0.04 (2.94 to 5.27) 0.01 (1.30 to 7.01)
Values are mean (SD) except for Coll 2-1, Coll 2-1 NO2 and the ratio of Coll 2-1 NO2/Coll 2-1 for which the results are median (range).changes observed after 1 year in any biochemical marker
and the long-term variations (3 years, DT36T0) of the
total WOMAC score or its subscales (data not shown).
At baseline, none of the analysed biochemical markers
were signiﬁcantly correlated with mean JSW. After 3-year
follow-up, mean JSW decreased signiﬁcantly by 0.31 mm
(Table II). There was no correlation between baseline levels
of biochemical markers and the 3-year change of JSW
(P between 0.10 and 0.13). However, there was a signiﬁcant
negative correlation between 1-year change (D T12 T0)
of Coll 2-1 and Coll 2-1 NO2 and the 3-year variation
(D T36 T0) of JSW (Coll 2-1: rZ0.31, PZ 0.03; Coll 2-
1 NO2: rZ0.31, PZ 0.03). No similar correlations were
found for Pyr and D-Pyr (P between 0.29 and 0.54)
(Table III).
In patients with 1-year changes in Coll 2-1 below the
median (less than 1.34 nM/mM), mean JSW decreased
by 0.23 mm (1.27), while patients with changes above this
value had a loss of JSW of 0.75 mm (0.96). When the
population was divided into quartiles of 1-year changes in
Coll 2-1, patients in the ﬁrst quartile (!3.11 nM/mM) had
a mean JSW increase of 0.11 (0.88) mm after 3 years,
whereas patients of the fourth quartile (OC1.05 nM/mM)
showed a decrease of 0.95 (0.11) mm (Fig. 1). In the fourth
quartile, 6/12 patients (50%) experienced a joint space
narrowing O0.5 mm over 3 years compared to 3/11
patients (27.3%) in the ﬁrst quartile. Similar observations
were made for Coll 2-1 NO2. Indeed, in the patients with
1-year changes in Coll 2-1 NO2 below the median
(!0.003 nM/mM), mean JSW decreased by 0.25
(1.07) mm, while patients with changes above this valuehad a loss in mean JSW of 0.75 (1.21) mm. When the
subdivision of our population into quartiles of 1-year
changes in Coll 2-1 NO2 was performed, patients in the
ﬁrst quartile (!0.010 nM/mM) had a mean JSW increase
of 0.25 (0.82) mm after 3 years, whereas patients of the
fourth quartile (OC0.007 nM/mM) showed a decrease of
0.95 (1.39) mm (Fig. 1). In the fourth quartile, 7/13 patients
(53.8%) experienced a joint space narrowing O0.5 mm
over 3 years compared to 2/11 patients (18.2%) in the ﬁrst
quartile.
The ratio of Coll 2-1 NO2/Coll 2-1 was also calculated.
This ratio of Coll 2-1 NO2/Coll 2-1 was not signiﬁcantly
correlated with the WOMAC score at baseline or with
its variation over 3 years (P between 0.38 and 0.96).
Furthermore, there was no relationship between Coll 2-1
NO2/Coll 2-1 and the importance or progression of joint
space narrowing (P between 0.60 and 0.71).
Finally, we have investigated the presence of correlations
between biochemical markers. In general, Coll 2-1, Coll 2-1
NO2 and Coll 2-1 NO2/Coll 2-1 were positively correlated
(Coll 2-1 and Coll 2-1 NO2: rZ 0.40, P! 0.001; Coll 2-1 and
Coll 2-1 NO2/Coll 2-1: rZ 0.67, P! 0.001; Coll 2-1 NO2 and
Coll 2-1 NO2/Coll 2-1: rZ 0.29, P! 0.01). On the other
hand, they were not correlated with Pyr or D-Pyr which were
correlated between themselves (rZ 0.82, P! 0.01).
Discussion
Type II collagen is the most abundant protein in the
cartilage. It is highly speciﬁc for this tissue suggesting thatTable III
Correlations between biochemical markers and WOMAC indices and radiographic parameter of knee joint space in patients with knee OA
Baseline biological markers vs WOMAC score One-year variation of
biological markers and
3-year variation of
radiographic parameter
Total score Pain Stiffness Function JSW
Coll 2-1 0.28* 0.27* 0.09 0.29* 0.31*
Coll 2-1 NO2 0.27* 0.30* 0.11 0.27* 0.31*
Coll 2-1 NO2/Coll 2-1 0.07 0.10 0.01 0.06 0.06
Pyr 0.08 0.05 0.01 0.10 0.08
D-Pyr 0.10 0.03 0.06 0.10 0.07
*P! 0.05.
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of cartilage degradation. For this reason, we have de-
veloped an immunoassay for measuring in biological ﬂuids
the sequence 108HRGYPGLDG116, named Coll 2-1, and
located in the triple helix part of the type II collagen. This
sequence is detectable only in its linear form released from
collagen type II by proteolysis, indicating that this peptide is
a marker of type II collagen network degradation20. Further,
this peptide contains one of the two tyrosines present in the
a chain, which are susceptible of nitration21. Therefore, to
evaluate the impact of reactive nitrated oxygen species on
type II collagen processing, we have calculated the ratio of
Coll 2-1 NO2/Coll 2-1. Coll 2-1 and Coll 2-1 NO2 were found
to be elevated in serum of OA and RA patients20. In-
terestingly, Coll 2-1 NO2/Coll 2-1 ratio was higher in RA
(0.25) than in OA patients (0.15) suggesting that Coll 2-1
nitration is related to synovium inﬂammation. Further, Coll
2-1NO2 but not Coll 2-1 was signiﬁcantly correlated with
C-reactive protein in serum of arthritic patients. These
results suggest that Coll 2-1 NO2 could be a promising
marker of arthritic disease activity. To our knowledge,
among various biochemical markers evaluating bone
[serum osteocalcin, serum and urinary C-telopeptide type
I collagen (CTX-I), Pyr, D-Pyr], cartilage [U-CTX-II, cartilage
oligometric matrix protein, serum human cartilage glyco-
protein 39 (S-YKL-40), serum keratan sulfate] and synovial
tissue (urinary glucosyl-galactosyl pyridinoline, serum type
III collagen N-propeptide, serum hyaluronic acid, serum C-
reactive protein) metabolism in patients with knee OA,
urinary glucosyl-galactosyl pyridinoline and serum osteo-
calcin were the only ones that correlate signiﬁcantly with the
total WOMAC score4. In this study, we have shown that
elevated urinary levels of Coll 2-1 and Coll 2-1 NO2 at
baseline were associated with a higher total WOMAC score.
This ﬁnding indicates that Coll 2-1 and Coll 2-1 NO2 urinary
levels, but not the levels of Pyr or D-Pyr reﬂect the clinical
severity of OA disease. However, neither baseline levels of
Coll 2-1 or Coll 2-1 NO2, nor their variations over 1 year
were predictive of the clinical progression of OA. This lack
of correlation might be explained in part by the low rate of
disease progression over 3 years in our experimental
population. Indeed, in our experimental population, the total
WOMAC score increased by only 9.8% over 3 years.
Fig. 1. Progression of joint damage over 3 years according to
quartile of 1-year variation of Coll 2-1 ( ) and Coll 2-1 NO2 (,).
Bars represent the mean value (SD) of the JSW in the highest
(Q4: 1-year variation of Coll 2-1: OC1.05 nM/mM and Coll 2-1
NO2: RG0.007 nM/mM) and lowest quartiles (Q1: 1-year variation
of Coll 2-1: !3.11 nM/mM and Coll 2-1 NO2: %0.010 nM/mM).Another objective of our study was to investigate whether
our biochemical markers were correlated with the radio-
logical severity of OA. At baseline, none of the biochemical
markers were correlated with the mean JSW of the medial
compartment of femorotibial joint. Some particular features
of our study may explain why our molecular markers did
not correlate at baseline with radiological OA lesions. At
baseline, our population was very homogeneous, probably
as a consequence of the restrictive criteria used for
inclusion. Patients had similar mild to moderate OA grading
and JSW at enrolment, with a degree of symptoms
expressed by the WOMAC index that was also similar
and of mild to moderate average severity. Therefore,
a larger study including patients with early and ﬁnal severe
stage of knee OA is needed before concluding on the
relationship between Coll 2-1 and Coll 2-1 NO2 urinary
levels and the severity of OA lesions. However, the main
goal of this longitudinal study was to assess the relationship
between biochemical marker urinary level changes over
time and the clinical and radiological progression. Among
the various biochemical markers, only Coll 2-1 and Coll 2-1
NO2 changes over 1 year, signiﬁcantly correlated with mean
JSW, increased levels being associated with increased joint
space narrowing. So a more severe joint space narrowing
after 3 years could be predicted by a greater increase in
Coll 2-1 or Coll 2-1 NO2 during the ﬁrst year. On the other
hand, baseline levels of Coll 2-1 and Coll 2-1 NO2 were not
correlated with the mean JSW progression over 3 years. In
a previous study, using the same patients cohort, we have
reported a weak correlation between baseline CTX-II and
the 3-year change in the JSW (rZ 0.27, PZ 0.03) and
a correlation between the 3-year change in the JSW and the
1-year change in CTX-II but only in a group of high turnover
OA patients having baseline CTX-II levels above the
meanC 1 SD of the reference population18. Taken together,
these ﬁndings indicate that Coll 2-1 and CTX-II, two peptides
released from type II collagen, give different information on
collagen scaffold degradation in OA cartilage, probably
because they are released at different stages of the type II
collagen ﬁbril processing. The degradation of collagen in
human arthritic cartilage is the result of initial cleavage by
a collagenase, followed by a secondary proteolytic process-
ing of the cleaved, denatured a chains2. The collagenases
cleave the triple helix between Gly975 and Leu976 to produce
the characteristic one-quarter and three-quarter pieces.
Recently, it was demonstrated that the C-terminal of the
collagenase generated 1/4 fragment is particularly suscep-
tible to proteolysis, and as a consequence that the
C-terminal (1/4 fragment) region of the type II collagen is
cleared faster from OA cartilage than the N-terminal (3/4
fragment) region13. Interestingly, CTX-II is located in the
C-telopeptide whereas Coll 2-1 is found in the a-helical part
of the protein near the N-terminal end, suggesting that
probably CTX-II is released earlier than Coll 2-1 from
cartilage.
In this study, Coll 2-1 and Coll 2-1 NO2 are similarly
correlated with clinical and radiological assessments,
indicating that, in this survey, peptide nitration is not
a modulated variable. Again, this ﬁnding can be explained
by the particular characteristics of our experimental
population. Our OA population had a mild to moderate
arthritis that slightly worsened over 3 years, indicating a low
disease activity. As Coll 2-1 nitration probably results of
oxidative cartilage damage, we can hypothesize that
oxidative stress does not occur in slowly progressive OA
but is a feature of rapidly progressive OA which is as-
sociated with an inﬂammatory process.
1064 M. A. Deberg et al.: Prediction of radiological OA progression by Coll 2-1In summary, urinary levels of Coll 2-1 and Coll 2-1 NO2 at
baseline, but not Pyr or D-Pyr, reﬂect the clinical activity of
knee OA. However, the markers were not predictive of
clinical disease progression. Furthermore, urinary Coll 2-1
level changes over 1 year are highly correlated with the
3-year changes of JSW, increased levels being associated
with increased joint space narrowing. In view of these
results, Coll 2-1 measurement at 1-year interval could help
the clinician to identify patients with high rate of joint
damage and then to decide which patient needs preventive
therapy (orthosis, devices, educational programs, environ-
mental adaptation) to stop or slow down OA progression.
Further, with the emergence of effective symptomatic
and/or structural treatments of OA, the measurement of
these novels, speciﬁc biochemical markers should be also
assessed in long-term clinical trials with the aim of
monitoring response to therapy appropriately.
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